Clinical trial Recruiting at 1 site Interventional Ages 30 to 65

VIVO 2nd GEN add-on for chronic low back pain with multimodal therapy

Official title: Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Within the Multimodal Pain Therapy (SENECA): A Randomized Controlled Pilot Study

Run by Aurimod GmbH · NCT07628179 · Data updated 2026-11-12

This pilot trial tests whether adding VIVO 2nd GEN auricular vagus nerve stimulation to standard multimodal pain therapy helps adults with chronic low back pain.

More Chronic Low Back Pain (CLBP) trials

Quick facts

Study typeInterventional
Ages30 Years to 65 Years
SexAll
Enrollment44 (estimated)
SponsorAurimod GmbH
Industry-sponsored
Locations1 site (Klagenfurt, Carinthia)
StatusRecruiting
StartedOctober 10, 2026
Main results expectedMay 31, 2027
Study endsNovember 30, 2027
Registry record updatedNovember 4, 2026
Trial IDNCT07628179 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 30–65 with chronic, intractable myofascial/musculoskeletal low back pain who have not fully responded to oral medications and meet study criteria.

Probably not a fit

Patients with organic back disease, recent back surgery, or high-opioid use may not benefit or be eligible for the benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized pilot study compares standard multimodal pain therapy alone versus standard therapy plus the VIVO 2nd GEN auricular vagus nerve stimulation in adults with chronic low back pain. Participants undergo baseline assessments of pain, quality of life, mood, and function, then receive their assigned treatment plan for a defined period. Outcomes will inform feasibility and usability of the device and its potential to improve pain, daily functioning, and quality of life when used alongside conventional care. The study uses a multimodal approach including physical therapy, aquatic therapy, exercise, and psychosocial support, with the device added for the treatment group. The next-generation device is used as an add-on therapy in this evaluation.

Why it matters

Potential benefit: If successful, patients may experience better pain control and improved daily functioning when adding VIVO 2nd GEN to standard care.

How similar studies have gone: Prior studies of neuromodulation approaches in chronic pain have shown promise, but this specific VIVO 2nd GEN addition in a multimodal program is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female aged between 30 and 65 years
* Indication: chronic myofascial/musculoskeletal back pain
* normal function of spinal nerves
* Intractable pain for more than 6 months
* Patient on oral pharmacotherapy ≤ WHO II with no adequate response or intolerant
* Average pain over the last 4 weeks according to the 0-10 numerical pain rating scale ≥ 4 and ≤ 9 at baseline
* ODI 20-80 at baseline
* Basic digital understanding to work with the patient pain app
* Patient understands the therapy and procedures, agrees to its provisions, and gives written informed consent prior to any procedures

Exclusion Criteria:

* Organic low back pain (trauma, fracture, tumor, infection, severe degenerative spine, documented high-grade spinal stenosis, rheumatologic conditions)
* Indication for back surgery
* Back surgery within the last 6 months
* New analgesics 2 weeks before baseline (paracetamol, NSAIDs, Metamizol, etc.)
* Opioid analgesic therapy \> WHO II
* New physical therapy modalities for back pain, also TENS, 2 weeks before baseline
* History of vagus nerve stimulation or electrical auricular stimulation
* History of vasovagal syncope
* High BMI \> 35 kg/m² (Obesity Class 2 or higher)
* Hemophilia
* Autonomic disorders
* Advanced stage or poorly controlled diabetes mellitus type I or II
* Poorly controlled high blood pressure
* Major psychiatric comorbidity (HADS \> 10 on each subscale at baseline)
* Other serious clinically relevant co-morbidity
* History of arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies
* Infection, eczema, or psoriasis at application site (ear and neck)
* Numbed and desensitized skin at the application site (ear and neck)
* Chronic drug or alcohol abuse within the last 6 months
* Pregnant or nursing female patients
* Active implantable device
* Open pension request
* Currently participating in another clinical trial or participated over the last 3 months
* Change in concomitant treatment or medication during the study

Where it's running

  • Klinikum Klagenfurt am Wörthersee
    Klagenfurt, Carinthia, Austria
    Recruiting

Study contacts

  • Principal investigator: Rudolf Likar, Prim. Univ.-Prof. Dr. MSc. — Klinikum Klagenfurt am Wörthersee
  • Study coordinator: Stefan Kampusch, DI
  • Email: s.kampusch@aurimod.com
  • Phone: +43 650 36 99 271

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.